ConductScience.org, home

Paper17513814

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

Eckardt JR and 9 others. J Clin Oncol, 2007. Cited by 288 papers, by iCite.

Cite this record

ConductScience Library. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. Papers, record 17513814. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17513814

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
PubMed
Journal
J Clin Oncol
PubMed
Year
2007
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
288
iCite
Relative citation ratio, by iCite
6.11
iCite
Revised in PubMed
2022-03-31
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Eckardt JRJohn R
2von Pawel JJoachim
3Pujol JLJean-Louis
4Papai ZZsolt
5Quoix EElisabeth
6Ardizzoni AAndrea
7Poulin RRuth
8Preston AJAlaknanda J
9Dane GGraham
10Ross GGraham

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Carcinoma, Small CellMajor topic
Liver NeoplasmsMajor topic
Lung NeoplasmsMajor topic
TopotecanMajor topic
Administration, Oral
Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Salvage Therapy
Survival Rate

Source PubMed

Download CSV of topics

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00003917Topotecan in Treating Patients With Relapsed Small Cell Lung CancerResultsClinicalTrials.gov
NCT02963090Pembrolizumab vs Topotecan in Patients With Small Cell Lung CancerBackgroundClinicalTrials.gov
NCT02980809Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung CancerBackgroundClinicalTrials.gov

Download CSV of trials

Cited by154

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 288 citations.

PMIDTitleJournalYearIn PapersSource
42908912Antibody-drug conjugates in advanced small-cell lung cancer: a systematic review and single-arm meta-analysis of later-line monotherapy.Front Immunol2026https://conductscience.org/library/papers/42908912PubMed
42840183The Five-Decade Journey of Small Cell Lung Cancer.Cancer Commun (Lond)2026https://conductscience.org/library/papers/42840183PubMed
42818024Topotecan Synergizes with SP141 in the Management of Uveal Melanoma.bioRxiv2026https://conductscience.org/library/papers/42818024PubMed
42523863Immunotherapy and the novel therapeutic development for small-cell lung cancer.Ther Adv Med Oncol2026https://conductscience.org/library/papers/42523863PubMed
42367288Efficacy and safety of nab-paclitaxel in advanced or recurrent small cell lung cancer: a single-arm meta-analysis.Front Pharmacol2026https://conductscience.org/library/papers/42367288PubMed
42174384
Real-World Data of Second-Line Amrubicin Monotherapy in Patients With Extensive-Stage Small Cell Lung Cancer Who Received First-Line Chemoimmunotherapy or Chemotherapy: A Multicenter Retrospective Study.
Cancer Med2026https://conductscience.org/library/papers/42174384PubMed
41562777Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC.Antibodies (Basel)2026https://conductscience.org/library/papers/41562777PubMed
41383089Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study.Thorac Cancer2025https://conductscience.org/library/papers/41383089PubMed
41234559Doxorubicin paclitaxel in pretreated advanced small-cell lung cancer: a large real-life retrospective study.Transl Lung Cancer Res2025https://conductscience.org/library/papers/41234559PubMed
41222788
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States.
Adv Ther2026https://conductscience.org/library/papers/41222788PubMed
41189556Place in therapy of key treatments for platinum-sensitive, relapsed, extensive-stage small cell lung cancer with a focus on lurbinectedin: a narrative review with case studies.Drugs Context2025https://conductscience.org/library/papers/41189556PubMed
41181839Efficacy and safety of tislelizumab plus anlotinib and irinotecan as second-line treatment for extensive-stage small cell lung cancer: a single-arm, open-label, phase II trial.EClinicalMedicine2025https://conductscience.org/library/papers/41181839PubMed
41055143IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer.Future Oncol2025https://conductscience.org/library/papers/41055143PubMed
40964483State of the art in treatment of small cell lung cancer.Ther Adv Med Oncol2025https://conductscience.org/library/papers/40964483PubMed
40866909
Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06.
BMC Cancer2025https://conductscience.org/library/papers/40866909PubMed
40596985Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer.BMC Cancer2025https://conductscience.org/library/papers/40596985PubMed
40583736Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.Thorac Cancer2025https://conductscience.org/library/papers/40583736PubMed
40240495Efficacy analysis and prognostic factors of first-line chemotherapy combined with immunotherapy in extensive-stage small cell lung cancer: a real-world study.Sci Rep2025https://conductscience.org/library/papers/40240495PubMed
40082695A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.Nat Med2025https://conductscience.org/library/papers/40082695PubMed
39897044Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer.Int J Biol Sci2025https://conductscience.org/library/papers/39897044PubMed

See all 154 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
TOPOTECAN HYDROCHLORIDECHEMBL1607Results1https://conductscience.org/library/drugs/CHEMBL1607

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17513814

GET https://conductscience.org/api/papers/v1/17513814/cited_by?page=2